Neuropace Inc. (NPCE) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Neuropace Inc. is a medical device company developing the RNS System, a brain-responsive neuromodulation system for treating drug-resistant focal epilepsy. The company operates as a single segment, with nearly all revenue generated in the United States. As of September 30, 2025, the company had approximately 33.3 million shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $27,354 | $21,060 | $73,398 | $58,440 |
| Gross Profit | $21,168 | $15,420 | $56,642 | $42,897 |
| Gross Margin | 77.4% | 73.2% | 77.2% | 73.4% |
| Net Loss | $(3,496) | $(5,452) | $(18,736) | $(21,891) |
| Net Loss Per Share (Basic/Diluted) | $(0.11) | $(0.19) | $(0.58) | $(0.76) |
| Cash, Cash Equivalents & Short-Term Investments | $60,014 | $52,755 | As of Sept 30, 2025 | |
| Long-Term Debt (Net) | $58,748 | $59,525 | As of Sept 30, 2025 | |
| Accumulated Deficit | $(549,686) | $(525,700) | As of Sept 30, 2025 |
Liquidity: The company reported cash used in operating activities of $11.5 million for the nine months ended September 30, 2025. Management believes current cash resources will fund operations for at least the next 12 months.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 30% year-over-year in Q3 2025 and 26% for the nine-month period, driven by higher RNS System unit sales, increased DIXI Medical product sales, and service revenue.
- Margin Expansion: Gross margin improved to 77.4% in Q3 2025 from 73.2% in Q3 2024, primarily due to lower fixed costs per unit from increased production volume, partially offset by lower margins on DIXI products.
- Debt Restructuring: In June 2025, the company repaid its CRG Term Loan ($61.9 million total obligation) using proceeds from a new $60.0 million MidCap Term Loan. This reduced the effective interest rate and extended the maturity to 2030.
- Equity Transactions: In February 2025, the company completed a follow-on offering raising $69.7 million net. Proceeds were used to repurchase all shares held by significant stockholder KCK Ltd. ($49.5 million) and for general corporate purposes. The At-the-Market (ATM) offering program was terminated in February 2025.
- Operating Expenses: Total operating expenses increased 21% in Q3 and 17% for the nine months, driven by increased personnel costs in sales, marketing, and R&D to support growth and clinical studies.
Guidance, Outlook, and Risks
- DIXI Medical Distribution Agreement: The exclusive distribution agreement with DIXI Medical expired on September 30, 2025. The company is in a six-month wind-down period to sell existing inventory. Future revenue growth will depend on the RNS System without DIXI revenue.
- Regulatory Outlook: The company plans to file an expanded label submission to the FDA for generalized epilepsy and pediatric patients (ages 12-17) prior to the end of 2025. Preliminary results from the NAUTILUS study for generalized epilepsy met safety endpoints but did not reach statistical significance for the primary effectiveness endpoint in the overall population.
- Financial Covenants: The MidCap Credit Agreement requires maintaining an Applicable Liquidity Threshold of at least $60.0 million until June 30, 2027. As of September 30, 2025, the company was in compliance with all covenants, with trailing 12-month net RNS System revenue of $77.0 million exceeding the minimum requirement.
- Risks: Key risks include the loss of DIXI revenue, reliance on single-source suppliers, potential delays in FDA approval for label expansion, and the need for additional capital if cash flow breakeven is not achieved as planned.
Investor Verification Checklist
- Debt Covenants: Verify continued compliance with the MidCap Credit Agreement liquidity and revenue covenants, specifically the $60.0 million liquidity threshold.
- DIXI Wind-Down: Monitor the impact of the DIXI Medical distribution agreement expiration on Q4 2025 and 2026 revenue projections.
- Regulatory Filings: Track the timeline and outcome of the planned FDA submission for expanded indications (generalized epilepsy and pediatric patients) expected before year-end 2025.
- Cash Burn Rate: Assess the sustainability of the current cash burn rate ($11.5 million operating cash outflow for 9M 2025) against the $60.0 million cash balance to confirm the 12-month runway.
- Supply Chain: Review disclosures regarding single-source suppliers for critical components (e.g., batteries, printed circuit assemblies) and any potential disruptions.